177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor
- 20 February 2021
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (5) , 415-418
Abstract
Prostate-specific membrane antigen (PSMA) overexpression in various tumors are demonstrated in both in vitro and in vivo studies. Prostate-specific membrane antigen–directed radionuclide therapies are generally used in prostate cancer and could be also useful in PSMA-avid other malignancies. Herein, we present a case of a 46-year-old male patient who had progressive metastatic testicular mixed germ cell tumor, despite repeated operations and treatments. 68Ga-PSMA PET/CT was performed to assess eligibility for 177Lu-PSMA therapy. Patient had intense PSMA uptake in metastatic lesions, and 177Lu-PSMA has been given to control of disease. However, α-fetoprotein level progressed, and mixed therapy response was detected in 68Ga-PSMA PET/CT.Keywords
This publication has 7 references indexed in Scilit:
- 177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma MultiformeClinical Nuclear Medicine, 2020
- Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CTClinical Nuclear Medicine, 2019
- Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the ParotidClinical Nuclear Medicine, 2019
- New Anti-Cancer Strategies in Testicular Germ Cell TumorsRecent Patents on Anti-Cancer Drug Discovery, 2019
- Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non–Small Cell Lung CancerClinical Nuclear Medicine, 2016
- 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human TissuesWorld Journal of Surgery, 2006